Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their blockbuster Dupixent in the I&I space, was “contrary to our expectations—we were ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous ...

Even as Sanofi and Regeneron angle to untangle their longstanding antibody-drug partnership, both drugmakers have planned to lean heavily on their split revenue from blockbuster Dupixent.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA‘s (NASDAQ:SNY) Phase 3 LIBERTY-CUPID Study C of Dupixent (dupilumab) was successful. The study met the primary and key secondary ...

Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...